An immunomodulatory medication called lenalidomide is essential for the treatment of malignancies such as multiple myeloma and myelodysplastic syndromes. Its exact mechanism of action, when taken orally, is still somewhat unknown but includes immune system modification and anti-tumor activities. It inhibits angiogenesis, which prevents the creation of new blood vessels that are essential for tumor growth, and is frequently used in combination therapy.